Buprenorphine and methadone for opioid addiction during pregnancy.
Academic Article
Review
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Buprenorphine and methadone are opioid-receptor agonists used as opioid substitution therapy during pregnancy to limit exposure of the fetus to cycles of opioid withdrawal and reduce the risk of infectious comorbidities of illicit opioid use. As part of a comprehensive care plan, such therapy may result in improved access to prenatal care, reduced illicit drug use, reduced exposure to infections associated with intravenous drug use, and improved maternal nutrition and infant birth weight. This article describes differences in patient selection between the two drugs, their relative safety during pregnancy, and changes in daily doses as a guide for prescribing clinicians.Copyright © 2014 Elsevier Inc. All rights reserved.
publication date
Research
keywords
-
Analgesics, Opioid
-
Buprenorphine
-
Drug Administration Schedule
-
Female
-
Humans
-
Methadone
-
Neonatal Abstinence Syndrome
-
Opiate Substitution Treatment
-
Opioid-Related Disorders
-
Practice Guidelines as Topic
-
Pregnancy
-
Pregnancy Complications
-
Pregnant Women
-
Prenatal Exposure Delayed Effects
-
Substance-Related Disorders
-
Treatment Outcome
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
number